Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U. Nowakowski GS, et al. Among authors: izutsu k. J Clin Oncol. 2021 Apr 20;39(12):1317-1328. doi: 10.1200/JCO.20.01366. Epub 2021 Feb 23. J Clin Oncol. 2021. PMID: 33621109 Free PMC article. Clinical Trial.
A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.
Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, Takahashi K, Oshima K, Kanda Y, Chiba S, Motokura T, Kurokawa M. Nitta E, et al. Among authors: izutsu k. Ann Oncol. 2007 Feb;18(2):364-9. doi: 10.1093/annonc/mdl393. Epub 2006 Nov 1. Ann Oncol. 2007. PMID: 17079695 Free article.
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R. Yamaguchi M, et al. Among authors: izutsu k. J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990393 Clinical Trial.
Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R. Ito Y, et al. Among authors: izutsu k. Clin Cancer Res. 2012 Aug 1;18(15):4183-90. doi: 10.1158/1078-0432.CCR-12-1064. Epub 2012 Jun 6. Clin Cancer Res. 2012. PMID: 22675173 Clinical Trial.
High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.
Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, Kaneko H, Kato K, Hasegawa Y, Chou T, Sugahara H, Henzan H, Sakamaki H, Suzuki R, Suzumiya J. Chihara D, et al. Among authors: izutsu k. Biol Blood Marrow Transplant. 2014 May;20(5):684-9. doi: 10.1016/j.bbmt.2014.01.025. Epub 2014 Jan 31. Biol Blood Marrow Transplant. 2014. PMID: 24492141 Free article.
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M, Ishizawa K, Maruyama D, Uike N, Ando K, Izutsu K, Terui Y, Imaizumi Y, Tsukasaki K, Suzuki K, Izumi T, Usuki K, Kinoshita T, Taniwaki M, Uoshima N, Suzumiya J, Kurosawa M, Nagai H, Uchida T, Fukuhara N, Choi I, Ohmachi K, Yamamoto G, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ogura M, et al. Among authors: izutsu k. Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29. Int J Hematol. 2017. PMID: 27900638 Clinical Trial.
[Treatment for mantle cell lymphoma].
Izutsu K. Izutsu K. Rinsho Ketsueki. 2017;58(10):2026-2032. doi: 10.11406/rinketsu.58.2026. Rinsho Ketsueki. 2017. PMID: 28978845 Japanese.
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, Do YR, Mun YC, Lee SR, Shin HJ, Suh C, Chuang SS, Lee YS, Lim ST, Izutsu K, Suzuki R, Relander T, d'Amore F, Schmitz N, Jaccard A, Kim WS. Kwong YL, et al. Among authors: izutsu k. Ann Oncol. 2018 Jan 1;29(1):256-263. doi: 10.1093/annonc/mdx684. Ann Oncol. 2018. PMID: 29077846 Free article.
Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study.
Ohmachi K, Ando K, Kinoshita T, Kumagai K, Hatake K, Ishikawa T, Teshima T, Kato K, Izutsu K, Ueda E, Nakai K, Kuriki H, Tobinai K. Ohmachi K, et al. Among authors: izutsu k. Jpn J Clin Oncol. 2018 Aug 1;48(8):736-742. doi: 10.1093/jjco/hyy087. Jpn J Clin Oncol. 2018. PMID: 30060000 Free PMC article. Clinical Trial.
501 results